Oncology Analytics’ Series B Yields $21M
The company will expand its health benefits management offerings, as well as make investments in data analytics and innovative health tech
Small Percentage of Cancer Cells Responsible for Metastatic Cancer Spread
Enabler cells containing a shortened oncoprotein in early-stage breast cancers could predict which tumors are more aggressive and destined to metastasize, report researchers from Georgetown University.
Democratizing Precision Medicine
In today’s world of precision medicine, the more information you have on a patient, the better, in terms of treatment options. The field of...
MSK’s Approved NGS-Based Tumor Panel Leads to FDA Assay Review Pathway
Memorial Sloan Kettering Cancer Center wins FDA authorization for MSK-IMPACT assay, the first tumor-profiling LDT to win agency approval
Sponsored: Making NGS Actionable—Moving Oncology Beyond ‘One Mutation-One Drug’
While most NGS providers limit their annotated reports to one mutation-one drug associations that address targeted therapeutics, Cellworks’ biosimulation platform permits an assessment of all cancer therapies, including radiation, chemotherapy, and immunotherapy.
Antibody-Producing Cells Last at Least One Year After COVID-19 Infection
A new study finds that nearly a year after recovering from COVID-19, the body’s bone marrow plasma cells still make active antibodies against the virus. The findings appear to suggest that antibody production does not wane over time to the point of offering no protection.
Graphene Hydrogel Could Help mRNA Vaccine Target Cancer More Effectively
A specialized hydrogel can not only encapsulate and protect mRNA cancer vaccines from being broken down in the body, but can also target lymph nodes to activate immune cells, shows early stage research.
KRAS Lung Cancer Drug Reaches Clinic via Accelerated FDA Approval
Amgen's Lumakras, a small molecule just approved for clinical use by the FDA, becomes the first targeted therapy for lung cancer patients with KRAS mutations, an urgently needed option for patients with limited therapeutic options.
Next Steps for Huntington’s Therapeutics Field After Roche, Wave Failures
Roche and Wave's Huntington's disease ASO trials failed earlier this year, but researchers in the field remain positive that a more effective therapy will be developed in the not too distant future.
SARS-CoV-2 Reproductive Method Could Be Good Target for Therapies
High quality microscopy has captured mammalian translation of SARS-CoV-2 viral RNA in unprecedented detail. The virus uses a ‘pseudoknot’ structure to create tension in the ribosome and promote frameshifting to translate viral RNA.
